How Often Do You Need Shingles Shots?

Most adults need just two shots of the shingles vaccine Shingrix, spaced two to six months apart, and that is the complete series. No booster dose is currently recommended after you finish those two shots. The schedule is straightforward, but a few situations change the timing or eligibility, and there is a meaningful difference between getting one dose and getting both.

The Standard Two-Dose Schedule

The CDC recommends two doses of Shingrix for immunocompetent adults aged 50 and older, with the second dose given two to six months after the first.¹ That window is fairly flexible. If life gets in the way and you miss the six-month mark, you do not need to restart the series. You just pick up where you left off and get the second dose when you can. The key point is that both doses are necessary to get the full level of protection the vaccine offers.

Unlike flu shots, which you need annually, or tetanus boosters every ten years, Shingrix is designed as a one-time, two-dose series. You walk into the pharmacy or your doctor’s office, get the first shot, come back a couple months later for the second, and you are done for the foreseeable future.

Why Getting Both Doses Matters

One dose of Shingrix still gives you partial protection, but the gap between one dose and two is significant enough that skipping the second shot leaves real value on the table. A large study looking at protection against two of shingles’ most dreaded complications found that full vaccination (both doses) was roughly 87% effective at preventing postherpetic neuralgia, the severe nerve pain that can linger for months or years after a shingles rash clears. A single dose dropped that protection to about 69%.²

The same study looked at herpes zoster ophthalmicus, a form of shingles that affects the eye and can threaten vision. Full vaccination was about 78% effective, while partial vaccination offered 68% protection.² So one dose is far better than nothing, but the second dose adds a meaningful bump, especially against the complications people worry about most.

If you got your first Shingrix shot months or even a year ago and never went back for the second, it is worth scheduling it now rather than starting over. The immune priming from the first dose persists, and there is no clinical reason to repeat it.

How Long Does Protection Last?

This is the question that really drives the “how often” concern. People want to know whether they will eventually need to come back for another round. The evidence so far is encouraging. In a follow-up extension of the two large pivotal trials behind Shingrix’s approval, vaccine efficacy remained at about 84% through a period spanning roughly five to seven years after vaccination. The immune response, measured both by antibody levels and by certain T cells trained to recognize the virus, had stabilized at a plateau well above pre-vaccination levels rather than continuing to decline.³

That plateau is a good sign. With many vaccines, antibodies climb sharply after vaccination and then drop steadily, and you can predict a point where protection will fade enough to warrant a booster. Shingrix antibody and T-cell levels appear to flatten out rather than nosedive, which suggests the protection has staying power. But Shingrix was only licensed in 2017, so we simply do not have 20- or 30-year data yet. Researchers are still following the original trial participants, and those ongoing studies will eventually tell us whether a booster becomes necessary.

Is a Booster Recommended Right Now?

No. As of current CDC guidance, there is no recommendation for a booster dose of Shingrix after you complete the initial two-dose series.⁴ If a pharmacist or doctor suggests you need one, they are getting ahead of the evidence. This could change in the future as longer-term data become available, but right now the two-dose series is considered sufficient.

This is actually one of the more common points of confusion. People who are used to annual flu shots or periodic tetanus boosters assume every vaccine needs regular refreshing. Shingrix does not, at least not yet. If you completed your two-dose series a few years ago, there is nothing additional to schedule.

A Faster Schedule for Immunocompromised Adults

People with weakened immune systems face a higher risk of shingles, and the virus tends to hit them harder. In 2021, the Advisory Committee on Immunization Practices expanded its recommendation to include adults aged 19 and older who are immunodeficient or immunosuppressed because of a disease or treatment. The standard two-dose schedule still applies, but with one key adjustment: the second dose can be given as soon as one to two months after the first for people who would benefit from a compressed timeline.⁵

This shorter window matters for someone about to start chemotherapy, begin an immunosuppressive drug for an autoimmune condition, or undergo an organ transplant. In those situations, there is a real advantage to getting both doses in before the immune system becomes severely compromised. The vaccine itself is not a live virus, so it is safe for immunocompromised people, which was a significant limitation of the older shingles vaccine.

Who falls into this category? People living with HIV, those on long-term high-dose corticosteroids, organ transplant recipients on anti-rejection drugs, people undergoing cancer treatment, and those with autoimmune diseases treated with biologic drugs or other immunosuppressants. If you are unsure whether your condition or medication qualifies, your doctor can clarify, but the general rule is that anything substantially lowering your immune function makes you eligible starting at 19 rather than 50.

If You Got the Older Shingles Vaccine

Before Shingrix came along, the only shingles vaccine available was Zostavax, a live-virus vaccine that was given as a single shot. Zostavax was discontinued in the United States in 2020 because Shingrix proved far more effective. If you received Zostavax years ago, you should still get the full two-dose Shingrix series. The CDC advises waiting at least eight weeks after a Zostavax dose before starting Shingrix.⁶

This is not because Zostavax did not work at all, but because its protection faded substantially over time. Studies showed Zostavax’s efficacy dropping well below 50% within a few years, whereas Shingrix maintains much higher protection over a longer period. If you are over 50 and your only shingles vaccination was Zostavax, consider yourself due for the Shingrix series regardless of when you got the older shot, as long as you respect that eight-week minimum gap.

What Happens If You Already Had Shingles

Having shingles once does not guarantee you will never get it again. The varicella-zoster virus remains dormant in your nerve cells for life, and it can reactivate more than once. The CDC recommends Shingrix for adults who have already had shingles, using the same two-dose schedule. There is no specific waiting period mandated, though most clinicians suggest waiting until the active rash has fully resolved before getting vaccinated, since your immune system is already busy fighting the virus during an active outbreak.

People who have had shingles are sometimes the most motivated to get vaccinated because they know firsthand how painful it can be. The nerve pain, the blistering rash along a single dermatome, the weeks of disruption: nobody wants that twice. Vaccination after a shingles episode is one of the more underused opportunities in preventive medicine.

Side Effects and Timing Practical Concerns

Shingrix has a reputation for producing noticeable side effects, and that reputation is earned. Soreness at the injection site is nearly universal, and many people experience fatigue, muscle aches, headache, or fever for a day or two after each dose. These reactions tend to be more pronounced than what you might expect from a flu shot. They are a sign that the vaccine’s adjuvant, a component designed to boost the immune response, is doing its job aggressively.

Because of these side effects, it is worth being strategic about timing. Getting the shot on a Friday afternoon so you have the weekend to recover is a common and sensible approach. Some people find the second dose produces stronger side effects than the first, though this varies. The discomfort is temporary and resolves within two to three days for the large majority of recipients.

These side effects are one reason some people get the first shot and never come back for the second. That reluctance is understandable but worth pushing past, given how much additional protection the second dose provides against the most serious shingles complications.²

Age and Risk Considerations

Shingles risk climbs steadily with age. About one in three people will develop shingles at some point in their lifetime, and the risk roughly doubles after age 60 compared to the decade before. Postherpetic neuralgia, the lingering nerve pain that is the most feared complication, also becomes more common and more severe in older adults. Someone who gets shingles at 75 is much more likely to end up with months of debilitating pain than someone who gets it at 52.

This is part of why the CDC set the age threshold at 50 for the general population. Your immune system’s ability to keep varicella-zoster virus locked away in dormancy weakens over time, and 50 is roughly where the risk curve starts bending upward noticeably. If you are between 50 and 60 and healthy, you might feel like shingles is a distant concern, but vaccination during this window means you are protected during the decades when risk is highest.

For younger adults under 50 who are not immunocompromised, Shingrix is not recommended. The risk-benefit calculation simply does not support it for that age group at population level. But for anyone who becomes immunocompromised before 50 due to medical treatment or disease, the expanded recommendation down to age 19 fills that gap.⁵

Cost and Insurance Coverage

Shingrix is not cheap. Without insurance, the two doses together can run over $300. Most private insurance plans and Medicare Part D cover Shingrix with no out-of-pocket cost for adults 50 and older, though you may need to confirm that your specific pharmacy is in-network. Under the Inflation Reduction Act, Medicare Part D enrollees pay zero cost-sharing for recommended vaccines including Shingrix, which removed a significant financial barrier that had previously kept vaccination rates low among older adults on Medicare.

For immunocompromised adults between 19 and 49, coverage can be less predictable. Because the ACIP recommendation covers this group, most commercial plans should cover it, but navigating insurance at those ages for a vaccine typically associated with older adults sometimes requires a prior authorization or a conversation with your insurer. If cost is a concern, the manufacturer offers a patient assistance program, and some state immunization programs or community health centers provide vaccines at reduced cost.

Vaccination rates for shingles remain lower than public health officials would like. Estimates suggest that fewer than a third of eligible adults have completed the Shingrix series. Part of this is the two-dose requirement itself, part is cost confusion, and part is the general sense that shingles “probably won’t happen to me.” Given that the vaccine prevents roughly five out of six cases of postherpetic neuralgia in fully vaccinated adults, the math favors getting both shots on time.²

1
Centers for Disease Control and Prevention. Shingles Vaccine Recommendations – Section: Routine recommendations
2
JAMA Network Open. Recombinant Zoster Vaccination and Risk of Postherpetic Neuralgia or Zoster Ophthalmicus – Section: Results
3
Oxford Academic. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70 – Section: RESULTS
4
Centers for Disease Control and Prevention. Shingles Vaccine Recommendations
5
PubMed Central. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 – Section: Clinical Guidance
6
CDC. Shingles Vaccine Recommendations – Section: For patients who previously received Zostavax